Quince Therapeutics, Inc. — Director's Dealing 2021

Nov 17, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cortexyme, Inc. (CRTX)
CIK: 0001662774
Period of Report: 2021-11-16

Reporting Person: LOWE CHRISTOPHER P. (COO & Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-11-16	Common Stock	M	30000	$2.23	Acquired	90000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-11-16	Stock Option (right to buy)	$2.23	M	30000	Disposed	2028-11-27	Common Stock (30000)	Direct

Footnotes

F1: The option will vest as to 25% of the shares on November 15, 2019, with the remaining 75% of shares vesting in equal monthly installments beginning on December 15, 2019 and ending on November 15, 2022.